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CD43 Modulates Severity and Onset of Experimental
Autoimmune Encephalomyelitis1
Mandy L. Ford,* Thandi M. Onami,* † Anne I. Sperling,‡ Rafi Ahmed,*† and
Brian D. Evavold2*
Experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis characterized by infiltration of acti-
vated CD4 T lymphocytes into tissues of the CNS. This study investigated the role of CD43 in the induction and progression of
EAE. Results demonstrate that CD43-deficient mice have reduced and delayed clinical and histological disease severity relative to
CD43/ mice. This reduction was characterized by decreased CD4 T cell infiltration of the CNS of CD43/ mice but similar
numbers of Ag-specific T cells in the periphery, suggesting a defect in T cell trafficking to the CNS. The absence of CD43 also
affected cytokine production, as myelin oligodendrocyte glycoprotein (MOG) 35–55-specific CD43/ CD4 T cells exhibited
reduced IFN- and increased IL-4 production. CD43/ CD4 MOG-primed T cells exhibited reduced encephalitogenicity rel-
ative to CD43/ cells upon adoptive transfer into naive recipients. These results suggest a role for CD43 in the differentiation and
migration of MOG 35–55-specific T cells in EAE, and identify it as a potential target for therapeutic intervention. The Journal of
Immunology, 2003, 171: 6527–6533.
E xperimental autoimmune encephalomyelitis (EAE)
3 is an
autoimmune attack on myelin-producing cells of the
CNS, which is initiated by CD4 T cells and character-
ized by an influx of activated lymphocytes and macrophages into
the brain and spinal cord parenchyma (1, 2). The experimental
condition results in localized inflammation and demyelination in
the CNS that leads to limb weakness and eventual paralysis (1, 2),
and mimics the human disease multiple sclerosis (MS) (3, 4). My-
elin oligodendrocyte glycoprotein (MOG) 35–55 is a well-charac-
terized target Ag of encephalitogenic T cells used to initiate EAE
in the H-2b C57B/6 mouse model (5).
Studies have shown that T cell trafficking to the CNS is a critical
factor in the ability of CD4 T cells to mediate disease (6). Ad-
hesion molecules facilitate the infiltration of lymphocytes into the
CNS of mice with EAE. Several reports have highlighted the im-
portance of the expression of integrins such as very late Ag-4 on
CD4 T cells that penetrate the blood brain barrier and mediate
disease (7, 8). In these studies, only clones expressing very late
Ag-4 could traffic to the CNS and thereby mediate EAE. Further-
more, up-regulation of ICAM-1, VCAM-1, and L-selectin on CNS
vessels correlated with the immigration of CD4 T cells during the
development of EAE (9). Thus, the ability of CD4 T cells to
migrate into the CNS is a critical parameter of their encephalito-
genicity. Determining factors that modulate T cell migration into
the CNS could lead to the development of effective therapeutic
intervention in MS.
CD43 (leukosialin, sialophorin) is a large sialoglycoprotein that
is abundantly expressed by cells of hemopoietic origin, including
both CD4 and CD8 T cells (10). Two distinct glycoforms of the
molecule exist, and their expression is differentially regulated in
CD4 and CD8 T cells (11, 12). CD43 has been implicated in the
regulation of both T cell homing and activation (10), and has been
shown to localize away from the immunological synapse by inter-
action with members of the ezrin-radixin-moesin family of cy-
toskeletal adaptor proteins (13–16). Early studies documented both
positive and negative regulatory roles for CD43 in T cell activation
(17–19), however these results may be reconciled by a recent re-
port suggesting that CD43 plays a dynamic role in the progression
of an immune response (12). Although earlier studies described a
negative regulatory role for CD43 on T cell adhesion (18, 20),
more recent studies have demonstrated a positive role for CD43 in
T cell homing to secondary lymphoid organs and peripheral tissues
(21–23). For example, anti-CD43 mAbs have been shown to pre-
vent the migration of T cells to pancreatic islets and thereby pre-
vent the development of diabetes in a nonobese diabetic model
(23). A potential role for CD43 in T cell homing to the CNS was
suggested in recent reports demonstrating delayed CD8 T cell mi-
gration into the CNS following intracranial infection of lymphocytic
choriomeningitis virus (LCMV) virus in CD43/ mice (12). In ad-
dition, increased expression of CD43 in the CNS was observed during
EAE (9). Therefore, we sought to characterize EAE induction and
progression in CD43/ mice and to analyze the ability of CD43/
T cells to adoptively transfer EAE. Our results indicate that disease is
significantly attenuated in CD43/ mice due to decreased lympho-
cyte trafficking to the CNS and cytokine dysregulation.
Materials and Methods
Mice
CD43/ B6.129 mice were originally generated by Ardman and cowork-
ers (18) and were purchased from The Jackson Laboratory (Bar Harbor,
ME) along with the CD43/ B6.129 wild-type control strain (H-2b).
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SCID mice (B6.CB17-Prkdcscid/SzJ) were purchased from The Jackson
Laboratory and housed in a sterile environment. Mice were bred and
housed in the Emory University Department of Animal Resources facility
(Atlanta, GA) according to Institutional Animal Care and Use Committee
protocols. For EAE experiments, mice were used at 8 wk of age.
EAE induction
EAE was induced according to the protocol of Mendel et al. (24). Briefly,
female B6.129 or CD43/ mice were immunized with 200 g of
MOG35–55 (MEVGWYRSPFSRVVHLYRNGK) emulsified in CFA con-
taining 5 mg/ml heat-inactivated Mycobacterium tuberculosis (H37 RA;
Difco, Detroit, MI) on days 0 and 7 s.c. in the hind flank (24). On days 0
and 2, mice received 250–500 ng of pertussis toxin (Sigma-Aldrich, St.
Louis, MO) i.p. Disease severity was monitored according to the following
scale: 0, no disease; 1, flaccid tail; 2, hind limb weakness; 3, hind limb
paralysis; 4, forelimb weakness; 5, moribund.
Histology
Spines were harvested and fixed in 10% formalin for 1 wk. Spinal cords
were then extracted, paraffin-embedded, and longitudinal sections were
stained with H&E for the presence of inflammatory infiltrates or Luxol fast
blue to detect demyelination. Inflammatory foci were scored in a blinded
fashion.
Flow cytometric analysis of brain lymphocytes
For analysis of lymphocytic infiltrates, mice with the highest disease score
in each group at the time point indicated were sacrificed. For day 25,
CD43/ mice ranged from 2.0 to 2.5 and CD43/ mice ranged from 0.0
to 2.5. For day 150, the CD43/ mice all had a score of 2.5 and the
CD43/ mice all had a score of 0.0. Brains were isolated and dissociated
in 10% FBS. Cells were resuspended in 100% Percoll (Sigma-Aldrich),
underlayed with 70% Percoll, and centrifuged at 2500 rpm for 20 min. The
interface was collected and cells were stained with anti-
CD4-allophycocyanin and anti-CD44-PE and analyzed by flow cytometry
on a BD FACSCalibur (BD PharMingen, San Diego, CA). Data were an-
alyzed using FlowJo software (Tree Star, San Carlos, CA).
Intracellular cytokine staining
Cultured splenocytes from MOG35–55-primed CD43
/ or CD43/ mice
(5  105 per well) were incubated in a 96-well plate with 100 M
MOG35–55 and 10 g/ml brefeldin A. After 6 h in culture, cells were
processed using an intracellular staining kit (Caltag Laboratories, San Di-
ego, CA) and stained with anti-CD4-allophycocyanin and anti-IFN--PE
(BD PharMingen). Data are gated on CD4 T cells.
Proliferation assay
Cultured splenocytes from MOG35–55-primed mice (5  10
5 per well) were
incubated in a 96-well plate with the indicated concentration of MOG35–55
peptide. After 48 h, cells were labeled with 0.4Ci/well [3H]thymidine.
Eighteen hours later, the plates were harvested on a FilterMate harvester
(Packard Instrument, Meriden, CT) and analyzed on a Matrix 96 Direct 
Counter (Packard Instrument).
IFN- and IL-4 ELISA
Splenocytes were incubated with 1 M MOG35–55 in a 24-well plate (5 
106/well) and supernatants were harvested 48 h later. Microtiter plates were
coated with 50 l of purified anti-IL-4 (5 g/ml, clone 11B11) or anti-
IFN- (2 g/ml, clone R4-6A2) overnight at 4°C. Captured cytokines were
detected using biotinylated anti-IL-4 (100 g/ml; BD PharMingen) or anti-
IFN- (clone XMG1.2, 100 g/ml; BD PharMingen) and detected using
alkaline phosphatase-conjugated avidin (Sigma-Aldrich) and p-nitrophe-
nylphoshphate (pNPP) substrate (Bio-Rad, Hercules, CA). Recombinant
IL-4 or IFN- (BD PharMingen) was used as a standard.
Measurement of MOG-specific Ab
Mice were sacrificed at various time points after EAE induction and pe-
ripheral blood was harvested by cardiac puncture. Blood was allowed to
clot at room temperature for 1 h and then overnight at 4°C. The clot was
microcentrifuged at 13,000 rpm for 5 min and serum was isolated. Micro-
titer plates were coated with 50 l of MOG35–55 peptide (5 g/ml) in
NaHCO3 coating buffer, pH 9.6, overnight at 4°C. Serum was titrated in
blocking buffer, plated at 100 l/well, and incubated overnight at 4°C (1/50
serum dilution is shown). Abs were detected using biotinylated anti-IgG1,
anti-IgG2a, anti-IgG2b, anti-IgG3 (BD PharMingen), avidin-conjugated al-
kaline phosphatase (Sigma-Aldrich), and pNPP (Bio-Rad). Colorometric
change was measured at 405 nm on a Microplate Autoreader (Bio-tek
Instruments, Winooski, VT).
Adoptive transfer of CD4 T cells for induction of EAE
CD43/ or CD43/ mice were immunized with MOG35–55 and lymph
nodes and spleens were harvested as described above. Lymph node cells
and splenocytes were cultured in vitro with 1 M MOG35–55 and IL-2 for
72 h. Cells were then Ficolled and CD4 T cells were positively selected
by MACS separation using magnetic CD4 microbeads (Miltenyi Biotec,
Auburn, CA) per manufacturer’s instructions. In one experiment, 2.5  106
CD4 T cells, and in a second experiment, 5  106 CD4 T cells, were
adoptively transferred by i.v. injection into SCID recipients on day 0. On
day 2, mice received an i.p. injection of pertussis toxin (250 ng), and mice
were then monitored for symptoms of disease. Because data were similar
for both experiments, the results were pooled.
Statistical analyses
Statistical analyses were conducted using GraphPad Prism (Software for
Science; GraphPad, San Diego, CA). Mean clinical scores were analyzed
by the Mann-Whitney test, while disease incidence percentages were com-
pared by Fisher’s exact test. Mean high scores, mean day of onset, and
mean day of peak disease were compared by Mann-Whitney test, and high-
est clinical scores were compared using the Student t test. Comparisons of
IFN- ELISA data and Ab production were performed using the Student
t test.
Results
CD43/ mice exhibit reduced EAE severity and incidence
Previous studies by Onami et al. (12) demonstrated that CD43/
mice exhibit delayed accumulation of CD8 infiltrates into the
FIGURE 1. CD43/ mice exhibit reduced EAE incidence and sever-
ity. CD43/ or CD43/ female mice were injected with MOG35–55 and
pertussis toxin and monitored for clinical signs of EAE. A, CD43/ mice
exhibit reduced disease severity during the course of disease. B, CD43/
mice have reduced disease incidence relative to CD43/ mice. Data
shown represent results obtained from immunization of 13 wild-type and
11 knockout mice in three independent experiments.
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CNS following intracranial infection with LCMV. Because CD43
is also expressed on activated CD4 T cells (11, 12), we hypoth-
esized that CD43 might play a role in EAE progression. To test this
hypothesis, B6.129 and B6.129 CD43/ mice were immunized
with MOG35–55 emulsified in CFA, injected with pertussis toxin,
and monitored for symptoms of disease (24–26). Results indicate
that CD43/ mice have reduced disease severity (Fig. 1A) and
disease incidence (Fig. 1B) compared with CD43/ mice in
MOG35–55-induced EAE. Whereas CD43
/ mice developed
EAE with a mean high clinical score of 3.1, CD43/ mice ex-
hibited a mean high clinical score of only 1.6 (Fig. 1C and Table
I). Of those CD43/ mice that did exhibit symptoms of disease,
none exhibited symptoms as severe as the majority of the
CD43/ mice (Fig. 1C), indicating that even among those mice
that got sick, the disease course was lessened. CD43/ mice also
exhibited a delay in disease onset relative to CD43/ mice, as the
average day of onset was day 14 and 19 after induction, respec-
tively (Table I). The day of peak disease in the CD43/ mice was
also delayed relative to wild-type controls (day 17 vs 24, respec-
tively) (Table I). Several CD43/ mice were observed up to 150
days postdisease induction and never exhibited the severe disease
symptoms seen in the CD43/ mice. In fact, by day 150,
CD43/ mice with a peak disease score of 2.0–2.5 had regressed
to a score of 0 (data not shown).
To confirm the finding that the generation of EAE is less severe
in CD43/ mice, longitudinal sections of spinal cord from con-
trol or CD43/ mice were examined in a blinded fashion for
FIGURE 2. Reduced infiltration and demyelination in spinal cords of
CD43/ EAE mice. Spinal cords were harvested from CD43/ or
CD43/ EAE mice 150 days after disease induction. Longitudinal sec-
tions were stained with H&E (A and C) or Luxol Fast Blue (B and D).
Sections from CD43/ mice exhibited less infiltration (B) and demyeli-
nation (D) relative to wild-type controls (A and C). Sections shown are
representative of those taken from three mice per group.
FIGURE 3. Reduced trafficking of CD4 T cells to the CNS in
CD43/ EAE mice. Brains from CD43/ or CD43/ EAE mice
were removed at day 25 or day 150 postdisease induction, stained with
anti-CD4, and analyzed by flow cytometry (A). Data were gated on live
cells and are expressed as the percentage of CD4 T cells within this
gate. Data from three mice per group from each time point are sum-
marized in B. For day 25, CD43/ mice ranged in disease score from
2.0 to 2.5 and CD43/ mice ranged from 0.0 to 2.5. For day 150, the
CD43/ mice all had a score of 2.5 and the CD43/ mice all had a
score of 0.0.
Table I. Clinical and histological features of EAE induced in CD43/ micea
Mean High Scoreb Incidencec Day of Onsetb Day of Peak Diseaseb
(Mean  SEM) (Day 20) (Day 40) (Mean  SEM) (Mean  SEM)
p  0.009 p  0.002 p  0.016 p  0.079 p  0.011
CD43/ n  13 3.1  0.2 100% 100% 13.7  0.4 17.2  0.4
CD43/ n  11 1.6  0.3 38% 54% 18.5  2.7 24.5  2.4
a Wild-type (CD43/, n  13) and CD43-deficient (CD43/, n  11) B6.129 mice were immunized for EAE with 200
g MOG35–55 emulsified in CFA and 250 ng of pertussis toxin. Results represent the cumulative data obtained from three
independent experiments.
b Mean high scores and day of onset/day of peak disease data are expressed as the mean  SEM. Statistical comparisons were
comparisons done using the Mann-Whitney nonparametric test.
c Comparison of disease incidence analyzed by Fisher’s exact test.
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inflammatory infiltrates and demyelination. Significantly less in-
flammatory infiltration and demyelination was identified in spinal
cord sections from CD43/ mice (Fig. 2, B and D) relative to
those obtained from wild-type controls (Fig. 2, A and C).
Reduced CD4 infiltrates into brains of CD43/ EAE mice
To determine whether the reduced disease severity seen in
CD43/ mice was due to decreased T cell trafficking to the brain,
CNS mononuclear cells from brain tissue of CD43/ or
CD43/ mice were examined for the presence of CD4 infil-
trates by flow cytometry following EAE induction. During both the
acute (day 25) and chronic (day 150) phases of disease, an in-
creased number of CD4 T cells were observed in CD43/ mice
relative to CD43/ mice at both time points (Fig. 3. The CD4
cells in the CNS were all CD44, consistent with an activated
phenotype that could mediate disease (data not shown). These re-
sults show that CD43/ mice lacked appreciable infiltration of
CD4 T cells in the CNS even 150 days post-EAE induction.
One interpretation of these data is that CD43/ MOG-specific
CD4 T cells have a defect in trafficking to the CNS, while an
alternative interpretation is that fewer CD4 T cells are activated
in response to immunization with MOG in CD43/ mice. To
determine the number of Ag-specific CD4 T cells in the periph-
ery of CD43/ EAE mice, splenocytes were analyzed by intra-
cellular IFN- staining after activation with MOG35–55. Results
indicated that splenocytes from CD43/ EAE mice contained
similar numbers of MOG35–55-specific T cells (Fig. 4A). Paradox-
ically, we observed increased proliferation (Fig. 4B) and IL-2 pro-
duction (data not shown) in response to MOG35–55 peptide in
CD43/ splenocytes relative to wild type. This result is consis-
tent with previous data suggesting that activated CD43/ T cells
exhibit decreased apoptosis in vitro (12). Thus, CD43/ mice
generate similar numbers of MOG35–55-specific CD4
 T cells, but
exhibit defects in CD4 T cell trafficking to the CNS.
Shift in cytokine profile in MOG35–55-specific CD43
/ T cells
Despite the similar numbers of IFN--positive T cells in wild-type
and CD43/ splenocytes, a difference in the mean fluorescence
intensity of the IFN- cells was observed (30%, data not shown).
To examine whether this decreased mean fluorescence intensity
indicated a reduction in IFN- production, cytokine levels were
examined by ELISA analysis of supernatants of cultured MOG-
specific T cells from CD43/ or CD43/ mice. We observed a
decrease in the amount of IFN- produced by CD43/ spleno-
cytes in response to MOG35–55 and a concomitant increase in IL-4
production (Figs. 5, A and B). These results suggested that
CD43/ MOG-specific T cells exhibited a less inflammatory cy-
tokine profile.
To confirm this finding and to further characterize the biological
impact of cytokine profile skewing, we examined the IgG subtype
profile of serum anti-MOG Abs in CD43/ or CD43/ mice.
The presence of IFN- in the extracellular milieu induces B cell
class switching to IgG2a, while the presence of IL-4 induces class
switching to IgG1 (27). A dramatic decrease in serum levels of
IgG2a and IgG2b was observed in CD43/ mice (Fig. 5C), con-
sistent with reduced IFN- needed to drive Ab class-switching to
IgG2a. Therefore, the decrease in MOG-specific IFN- observed
in CD43/ mice is biologically significant. No change in the
levels of IgG1 or IgG3 was observed (Fig. 5C). Overall, these data
suggest that in addition to a defect in CD4 T cell trafficking to the
CNS, CD43/ CD4 T cells also exhibit a less inflammatory
response consistent with decreased disease in an EAE model.
Delayed onset of adoptive transfer EAE in recipients of CD43/
 CD4 T cells
Because CD43 is expressed on many cell types of hemopoietic
origin, the effect of the loss of CD43 on CD4 T cells was spe-
cifically investigated. To accomplish this, CD43/ or CD43/
mice were primed with MOG35–55, and their lymph nodes were
harvested 10 days later and restimulated in vitro with specific pep-
tide. CD4 T cells were then purified and adoptively transferred
into B6 SCID recipients. Staining with CD44 revealed a similar
number of CD44high cells in both the CD43/ and CD43/
FIGURE 4. Hyperproliferation and equivalent IFN- production by
CD43/ MOG-primed splenocytes. Splenocytes from CD43/ or
CD43/ EAE mice were harvested and restimulated with 10 M
MOG35–55 for measurement of intracellular IFN- (A) or various concen-
trations of MOG35–55 in a proliferation assay (B). Data shown are repre-
sentative of three independent experiments using pooled splenocytes from
two to four mice per group.
FIGURE 5. Splenocytes from CD43/ EAE mice exhibit reduced
IFN- and increased IL-4 in response to MOG35–55. CD43
/ or CD43/
MOG-primed splenocytes were restimulated in vitro with 10 M
MOG35–55 for 48 h, and supernatants were analyzed for the presence of
IFN- (A) or IL-4 (B) by ELISA. Serum was also collected from CD43/
EAE mice and analyzed for the presence of anti-MOG35–55 IgG by ELISA.
Data shown are representative of three independent experiments using
pooled splenocytes from two to four mice per group. , p  0.01.
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cultures (40%, data not shown), suggesting a similar number of
Ag-specific cells were transferred in both groups.
Results demonstrate a striking difference in the day of disease
onset, with a mean day of onset of 5.5 in the recipients of
CD43/ CD4 cells compared with 11.3 in the recipients of
CD43/ CD4 T cells (Table II). Although the disease severity
in adoptive transfer recipients was less robust overall than that
observed in immunized mice, results indicate a moderate decrease
in the mean high score in recipients of CD43/ CD4 T cells as
compared with CD43/ T cells (2.2  0.1 vs 1.4  0.2) (Fig. 6A,
Table II). A significant difference in disease incidence was also
detected over the course of the disease (Fig. 6B, Table II). These
results indicate that CD43/ CD4 T cells have a reduced and
delayed ability to induce EAE as compared with wild-type CD4
T cells, and suggest that the observed decrease in disease severity
in CD43/ mice is due to the absence of CD43 on CD4 T cells.
Adoptive transfer recipients of CD43/ T cells exhibit skewed
cytokine profile
To determine whether the CD43/ adoptively transferred T cells
exhibited a skewed cytokine profile relative to recipients of
CD43/ CD4 MOG-primed T cells, splenocytes were isolated
from adoptive transfer recipients on day 26 posttransfer. After re-
stimulation with MOG35–55 in vitro for 72 h, supernatants were
analyzed by ELISA. Results indicate that splenocytes from recip-
ients of CD43/ mice exhibited reduced IFN- secretion and
increased IL-4 secretion (Fig. 7). These data corroborate the results
of in vivo immunization experiments in CD43/ mice that sug-
gest a role for CD43 in determining Th cell phenotype. Interest-
ingly, T cells isolated from adoptive transfer experiments exhibited
a much more dramatic shift in cytokine phenotype than T cells
isolated from immunized mice (Fig. 4).
Discussion
In this study, we addressed the induction and progression of
MOG35–55-induced EAE in CD43-deficient mice. A dramatic re-
duction in disease severity was observed in CD43/ mice as
FIGURE 6. Adoptively transferred CD43/ CD4 MOG-primed T
cells are less encephalitogenic than their wild-type counterparts. MOG-
primed T cells from CD43/ or CD43/ donors were stimulated in vitro
for 72 h, MACS-sorted for CD4 T cells (85% purity was achieved), and
transferred i.v. into SCID recipients (2  106 CD4 cells/mouse in the first
experiment and 5  106 cells/mouse in the second). Recipients also re-
ceived an injection of pertussis toxin on day 2 posttransfer. Mice were then
monitored for the symptoms of EAE. Because data obtained was similar in
both experiments, results were pooled. Recipients of CD43/ MOG-
primed CD4 T cells exhibited reduced disease severity (A) and disease
incidence (B) relative to recipients of CD43/ cells. Values of p were
calculated by Mann-Whitney test comparing disease scores during days
4–26 (those after disease onset in recipients of wild-type cells).
FIGURE 7. Splenocytes from recipients of CD43/ MOG-primed T
cells exhibit reduced IFN- and increased IL-4 secretion. Splenocytes from
adoptive transfer recipients at day 26 posttransfer and restimulated in vitro
with 10 M MOG35–55. Forty-eight hours later, supernatants were har-
vested and assayed for IFN- and IL-4 by ELISA. Data are representative
of three individual mice from two independent experiments.






(Mean  SEM)(Day 8) (Day 18)
p  0.038 p  0.023 p  0.01
CD43/ n  7 2.2  0.1 6/7 (86%) 6/7 (86%) 5.5  0.5
CD43/ n  5 1.5  0.3 1/5 (20%) 4/5 (80%) 11.3  1.7
a Wild-type (CD43/) and CD43-deficient (CD43/) CD4 MOG-primed T cells were adoptively transferred into SCID
mice (2–5  106 T cells/mouse) on day 0. Mice received an injection of pertussis toxin (250 ng) on day 2. Results represent
cumulative data obtained from two independent experiments.
b Results are expressed as the mean (SEM). Comparisons analyzed by Mann-Whitney nonparametric test; only those mice
that developed disease were included in the analysis.
c Comparison of disease incidence analyzed 2 test.
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compared with their wild-type counterparts (Fig. 1). This reduction
in disease severity was not due to a global defect in T cell acti-
vation, as knockout and wild-type mice exhibited similar numbers
of Ag-specific T cells in the spleen, and CD43/ MOG-specific
T cells proliferated very well in response to MOG peptide (Fig. 4).
Instead, our results demonstrate that in the absence of CD43,
MOG-specific T cells exhibited significantly reduced homing into
brain and spinal cord tissue and produced less IFN- and more
IL-4 (Figs. 2, 3, and 5). This defect in CNS trafficking could be
directly due to the absence of CD43, which has been reported to be
an adhesion molecule important in the migration of cells to pe-
ripheral tissue. This has been suggested in other model systems;
for example, anti-CD43 mAbs have been shown to prevent the
migration of T cells to pancreatic islets and thereby prevent the
development of diabetes in nonobese diabetic mice (23). Our data
suggest the loss of CD43 ameliorates disease in an EAE model,
and therefore further support an important role for CD43 in lym-
phocyte migration. Importantly, these results identify CD43 as a
potential target for therapeutic intervention in EAE and MS.
The results of this study also revealed, however, that MOG-
specific CD43/ exhibit a less inflammatory cytokine profile,
suggesting that the absence of CD43 during T cell activation has
functional consequences for the differentiation of Th cells. Similar
findings have been identified, concluding that CD43/ T cells
with a variety of Ag-specificities (including MOG35–55) exhibit a
Th2 profile (A. I. Sperling, unpublished data). Although the ob-
served increase in IL-4 production by CD43/ T cells was sta-
tistically significant (Fig. 5B), the lack of concomitant increase in
IgG1 levels (Fig. 5C) and the absence of eosinophilic infiltration in
the spinal cord (data not shown) suggest that it may not be bio-
logically significant. In contrast, a dramatic decrease in serum lev-
els of IgG2a was observed (Fig. 5C). Several reports suggest that
anti-myelin IgG2a may be better able to fix complement than IgG1
(28–30), and anti-myelin IgG2a has been shown to exacerbate
disease in vivo (30). Furthermore, the secretion of IFN- by au-
toreactive T cells is known to result in the activation of resident
microglia and later cause the influx of activated peripheral mac-
rophages that then release inflammatory mediators that damage
oligodendrocytes and inhibit the production of myelin (1, 2).
Therefore, the reduction in IFN- may be more responsible for the
observed decreased disease severity observed in CD43/ mice.
Although it is possible that reduced T cell trafficking and altered
cytokine profile independently contribute to the amelioration of
disease, it is also possible that a causative relationship exists be-
tween the two. Evidence exists that suggests a shift from Th1 to
Th2 phenotype could be directly responsible for deficits in T cell
homing. For example, Th1 cells have been shown to express che-
mokine receptors CCR5 and CXCR3, whereas Th2 cells primarily
express CCR4 and CCR8 (31–33). Encephalitogenic T cells and
those isolated from lesions in MS patients express CCR5 and
CXCR3 and migrate toward RANTES and macrophage inflamma-
tory protein-1 (34). In addition, Austrup et al. (35) demonstrated
that only Th1 cells could bind to P- and E-selectin and thereby
efficiently migrate to sites of inflammation. Therefore, it is possible
that the phenotype shift itself could contribute to the observed
decrease in lymphocyte trafficking to the CNS. Preliminary results
indicate that there is no difference in the level of CCR5 expression
on CD43/ MOG35–55-primed T cells as compared with wild-
type controls (M. L. Ford and B. D. Evavold, unpublished obser-
vations). Experiments to examine patterns of expression of other
chemokine receptors are ongoing.
CD43 is highly expressed on many hemopoetic cell types, in-
cluding T cells, B cells, granulocytes, and monocytes. Our adop-
tive transfer studies using CD43/ or CD43/ MOG-primed
donor T cells demonstrate that the absence of CD43 on T cells
negatively affects their ability to induce EAE in SCID recipients.
SCID recipients were used in our studies to minimize potential
minor histocompatibility-specific responses among B6.129 F2 hy-
brid mice. Several groups have documented enhanced EAE induc-
tion in SCID mice after adoptive transfer of myelin-specific mu-
rine T cells (36). Both CD43/ and CD43/ T cells undergo
homeostatic proliferation following transfer into lymphopenic
hosts (data not shown), leading to an expanded population of en-
cephalitogenic T cells. A delay in disease onset and lower disease
severity was observed in the recipients of CD43/ T cells (Fig.
6), indicating that at least a portion of the reduced disease severity
seen in the CD43/ mice is due to the effect on T cells. Analysis
of adoptive transfer of CD43/ CD4 T cells into CD43/
recipients may reveal an additional role for CD43 on other cell
types during the induction and progression of EAE.
The results of our experiments both in the CD43/ immunized
mice (Fig. 1, Table I) and the recipients of adoptively transferred
CD43/ cells (Fig. 6, Table II) reveal a delay in disease kinetics
relative to wild-type counterparts, suggesting CD43/ T cells
may be delayed in trafficking to the CNS. This finding is substan-
tiated by the observation that CD8 T cells exhibited a delay in
trafficking to the CNS following intracranial infection (12). How-
ever, in the viral model, the short delay in T cell trafficking did not
protect the mice from the effects of an inflammatory immune re-
sponse in the brain, and all died a few days after their wild-type
counterparts (12). In contrast, the apparent delayed kinetics of
CD43/ migration in the EAE model impacted the overall se-
verity of disease, in that CD43/ mice never exhibited severe
disease (Fig. 1, Table I). The fact that delayed kinetics did not
affect the eventual outcome during acute viral infection but does
seem to impact the immune response to a self-Ag may be ex-
plained by the robustness of the immune response in the two in-
stances. Although viral infections such as LCMV present high
doses of Ag and induce a strong and sustained immune reaction,
the immune response to low dose, self-Ags is much weaker and
therefore may be more susceptible to the absence of auxiliary fac-
tors such as CD43. The results from both the immunization and
adoptive transfer experiments indicate that CD43/ T cells are
capable of mediating a less severe and delayed disease, suggesting
that CD43 is just one element capable of modulating a complex
and multifactorial disease process. It is possible that effective ther-
apy for the treatment of MS will be combinatorial in nature, and
require targeting several different facets of the autoreactive im-
mune response.
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